# NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

> **NCT05773859** · PHASE1,PHASE2 · RECRUITING · sponsor: **Radboud University Medical Center** · enrollment: 10 (estimated)

## Conditions studied

- Epithelial Ovarian Cancer
- Ovarian Carcinoma

## Interventions

- **BIOLOGICAL:** XP-DC vaccinations

## Key facts

- **NCT ID:** NCT05773859
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-17
- **Primary completion:** 2026-03
- **Final completion:** 2026-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05773859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05773859, "NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05773859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*